Technological University Dublin

ARROW@TU Dublin
Articles

School of Biological Sciences

2017

Outcomes of exclusive enteral nutrition in paediatric Crohn's
disease
L. Lafferty
M. Tuohy
A. Carey

See next page for additional authors

Follow this and additional works at: https://arrow.tudublin.ie/scschbioart
Part of the Pediatrics Commons
This Article is brought to you for free and open access by
the School of Biological Sciences at ARROW@TU Dublin.
It has been accepted for inclusion in Articles by an
authorized administrator of ARROW@TU Dublin. For more
information, please contact arrow.admin@tudublin.ie,
aisling.coyne@tudublin.ie, gerard.connolly@tudublin.ie.
This work is licensed under a Creative Commons
Attribution-Noncommercial-Share Alike 4.0 License

Authors
L. Lafferty, M. Tuohy, A. Carey, Sheila Sugrue, M. Hurley, and Seamus Hussey

European Journal of Clinical Nutrition (2017) 71, 185–191
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0954-3007/17
www.nature.com/ejcn

ORIGINAL ARTICLE

Outcomes of exclusive enteral nutrition in paediatric
Crohn’s disease
L Lafferty1,2,6, M Tuohy1,2,6, A Carey2,3, S Sugrue1, M Hurley2 and S Hussey2,3,4,5
BACKGROUND/OBJECTIVES: Exclusive enteral nutrition (EEN) is a safe and effective treatment modality for inducing remission in
paediatric Crohn’s disease (CD). The primary aim of this study was to compare the outcomes of EEN to corticosteroid (CS) therapy in
newly diagnosed, treatment-naïve patients with CD. A secondary aim was to describe the outcomes of EEN in a national cohort of
paediatric CD patients over a 10-year period.
SUBJECTS/METHODS: A retrospective chart review was conducted at the Irish national referral centre for paediatric CD. A casematched analysis was conducted on two cohorts matched for age, gender, disease location, disease behaviour and disease activity,
who received CS or EEN as their initial treatment. Subsequently, cohort analysis was conducted on all patients who undertook a
course of EEN therapy between 2004 and 2013.
RESULTS: The case-matched analysis found higher remission rates after treatment with EEN (24/28, 86%) compared with those with
CS (15/28, 54%; P = 0.02). Dietetic contacts were found to be pivotal to the success of treatment and the attainment of remission. In
total, 59 patients completed EEN at some time-point in their disease course and were included in the cohort analysis. Sixty-nine per
cent of this cohort entered clinical remission (41/59). EEN was found to be most effective when used as an initial treatment
(P = 0.004) and less effective in patients aged under 10 years (P = 0.04).
CONCLUSIONS: EEN should be strongly considered as a favourable primary treatment over CS, especially in those diagnosed over
the age of 10 years.
European Journal of Clinical Nutrition (2017) 71, 185–191; doi:10.1038/ejcn.2016.210; published online 23 November 2016

INTRODUCTION
Crohn’s disease (CD) is a chronic inﬂammatory condition
characterised by periods of relapse and remission.1–3 It may
present at any age, with ~ 25% of all cases diagnosed during
childhood and adolescence.4–6 In Ireland, there has been a
substantial and sustained increase in the incidence of childhood
CD over the past 10 years.7
Interactions between the environment, host susceptibility and
immune-mediated tissue injury are implicated in CD
pathogenesis.6,8 In addition to the common presenting clinical
symptoms of diarrhoea, abdominal pain and weight loss,1,9
children are at increased risk of impaired linear growth, delayed
pubertal development and poor bone health.2,10 Childhood-onset
inﬂammatory bowel disease (IBD) is characterised by more
extensive disease location and more aggressive disease behaviour
than adult-onset disease.11,12
The choice of induction treatment is inﬂuenced by factors
including disease phenotype and activity, with exclusive enteral
nutrition (EEN) and corticosteroids (CS) predominantly used as
ﬁrst-line induction paediatric therapies. EEN refers to the
administration of an enteral formula either orally or via a feeding
tube for a 6- to 8-week period, followed by the gradual
reintroduction of normal diet.8,13–15 Recent guidelines advocate
the use of EEN as induction treatment for children with
inﬂammatory luminal disease.16 Comparable paediatric remission

rates have been reported following treatment with either EEN
or CS.17–20 The potential beneﬁts of EEN extend beyond nutrition
alone, and include improved mucosal healing, linear growth and
bone health.19,21–24 Although CS is clinically efﬁcacious and
associated with improvements on endoscopic assessment, mucosal healing is not superior to that seen with EEN.22,23 Their use is
also associated with undesirable side effects including weight
gain, striae, linear growth impairment, acne and low mood.25,26
In this study we sought to compare the outcomes of patients
treated with EEN at diagnosis to a cohort treated with CS at
diagnosis, matched for age, gender, disease location, disease
behaviour and disease activity. We subsequently evaluated the
outcomes of all patients completing a course of EEN as an
induction therapy to determine the factors inﬂuencing its efﬁcacy.
SUBJECTS AND METHODS
Study design
In Ireland, the National Centre for Paediatric Gastroenterology at Our
Lady’s Children Hospital Crumlin (OLCHC) is the sole provider of specialty
paediatric gastroenterology services. For the ﬁrst part of this study (casematched analysis), we compared the outcomes of EEN to CS therapy when
used as the ﬁrst induction treatment in a cohort matched for age, gender,
disease location, disease behaviour and disease activity. The second part of
the study (cohort analysis) involved a retrospective case review to examine
the clinical outcomes of all patients who completed EEN at any stage of
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their disease course in this nationally representative cohort from 2004 to
2013. This study was conducted with the approval of the research ethics
committee of OLCHC.

Treatment protocols
A course of EEN was deﬁned as per our hospital protocol. The hospital EEN
protocol involves taking a liquid enteral formula (polymeric or elemental,
depending on patient taste preference), either orally or via a feeding tube,
as the sole nutritional source for 6–8 weeks' duration. Patients who have
not been fully established on EEN by day 7 are given an alternative
induction treatment, but can stay on partial/supplemental EN. The protocol
permits negligible amounts of non-nutritive treat foods (jelly, boiled
sweets and chewing gum) that have an insigniﬁcant caloric value. This is
then followed by the gradual reintroduction of normal diet over a 2-week
period. A breech of EEN protocol was deﬁned as a requirement for
extension of EEN therapy to induce remission, or the need to use CS or
biologics as concomitants or alternatives to an already established EEN
course. The hospital protocol for oral CS therapy involves prednisolone
1 mg/kg (maximum 40 mg) daily for 4 weeks, followed by a weekly 5 mg
wean over the subsequent 7 weeks. A breech of CS protocol was deﬁned
as the requirement to either prolong CS course, to reduce the rate of CS
taper or to use adjunctive EEN or biologics to induce remission.

Patient selection
For the purpose of the case-matched analysis, patients were eligible for
inclusion if they took EEN as their initial primary treatment upon diagnosis
(⩾7 days, up to 6–8 weeks total duration). Each EEN patient was
individually best matched in terms of age (±1 year), gender, disease
location, disease behaviour and disease activity with a CS candidate.
Patients were excluded from the case-matched analysis if they had
received previous treatment for CD, if EEN was not fully established within
7 days of starting, if concomitant CS or biologics were commenced
simultaneously with EEN treatment (EEN group) or if EEN or biologics were
used during CS treatment (CS group). Other concomitant medications did
not exclude patients from either cohort but were documented.
A subsequent cohort review included all paediatric patients who
undertook a course of EEN therapy during the study period, as per
hospital protocol, irrespective of disease stage or duration. Patients with a
diagnosis of ulcerative colitis or IBD-unclassiﬁed or patients for whom EEN
was not the sole source of nutrition were excluded. Concomitant
medications were documented but did not exclude patients from the
cohort. Treatments with EEN were classiﬁed as ‘initial’ (primary induction
agent at ﬁrst diagnosis), ‘subsequent’ (second-line induction agent within
3 months of diagnosis) or ‘relapse’ (commenced to treat a disease relapse
in a patient previously in remission).

Study deﬁnitions and data collection
Children were diagnosed according to established international clinical,
radiological, endoscopic and histological criteria.27 Clinical assessments
and decisions were made by an attending consultant gastroenterologist.
Disease phenotype (location and behaviour) and age of diagnosis were
deﬁned using the Paris classiﬁcation criteria.28 Disease activity was deﬁned
using the Paediatric Crohn’s Disease Activity Index (PCDAI).29 A Physician
Global Assessment score of the attending consultant gastroenterologist
was also recorded in parallel, to ascribe disease activity before and after
treatment (0 = inactive, remission; 1 = mild activity; 2 = moderate activity;
3 = severe activity).30
Data were collected by two independent investigators (MT, LL) from
existing hospital databases, medical and dietetic records and recorded on
study-speciﬁc case report forms. Data were veriﬁed by a senior investigator
(AC) and any errors or inconsistencies were resolved with the senior author
(SH). The hospital records include a pro forma IBD clinic sheet, which
includes listing all elements of PCDAI for each clinical assessment. PCDAI
scores were calculated retrospectively from these clinic sheets by two
investigators before and after treatment. Remission was deﬁned as a PCDAI
of ⩽ 10. Mild disease was classiﬁed as a PCDAI of 11–30, moderate disease
31–44 and severe disease ⩾ 45.28 Albumin, haematocrit, erythrocyte
sedimentation rate, haemoglobin, platelets and C-reactive protein were
recorded before and after treatment. These laboratory values form part of
the PCDAI score and are ordinarily assessed at patient visits. Our IBD
service had a single senior dietitian across the duration of the study period.
The dietetic records contained details including the type, duration and
mode of administration of enteral formula, and details of any extraneous
European Journal of Clinical Nutrition (2017) 185 – 191

foods consumed during treatment, as reported by patients and/or families.
Dietetic contacts were deﬁned as indirect (telephone or email, sourced
from the hospital’s health information system) or direct (outpatient
appointment or in-patient visit) to allow for a detailed analysis of dietetic
resources in EEN service provision. Additionally, all medical and clinical
nurse specialist contacts were documented. Nutritional requirements were
calculated based on 120% of the Reference Nutrient Intake as
recommended in the current literature.31 Patients’ intakes were then
compared against requirements to assess nutritional adequacy.
The duration from remission to subsequent relapse, along with the
number of relapses from the point of remission to 1 year after treatment
were documented. A relapse was deﬁned as an increase in disease activity
necessitating a repeat course of EEN or CS, an escalation of medical
treatment or surgery. Disease progression was deﬁned as a progression in
disease behaviour or extension of disease location from baseline
diagnostic phenotype, as deﬁned by the Paris classiﬁcation.28 Subsequent
medication use after treatment was documented.
Weight and height z-scores were calculated using the LMS Growth Excel
package (Harlow Printing Limited, Newcastle, UK). Growth delay was
classiﬁed as a height z-score of o − 2 at diagnosis, or a reduction in height
z-score of ⩾ 0.75 from diagnosis to 1 year after treatment.26 Geographic
residency of patients was classiﬁed as ‘rural’ or ‘urban’ using Ireland’s
Central Statistics Ofﬁce Small Area Population Statistics interactive
mapping tool. A location with o 1500 inhabitants was deﬁned as
‘rural’.32 Anthropometric measurements were examined at four timepoints: pre-treatment, post-treatment, at 1 year and at maximum followup. Maximum follow-up was deﬁned as the last documented outpatient
appointment or in-patient stay at the time of data collection or before
discharge to adult services.
For the case-matched analysis, additional data recorded included type,
dosage, route of administration and duration of treatment (including
tapering period) of CS therapy.

Statistical analysis
Statistical analysis was performed using Statistical Package for the Social
Sciences (Version 22; SPSS, Chicago, IL, USA). Categorical data, such as
baseline subject characteristics, were analysed using descriptive statistics.
To investigate associations between categorical variables, χ2 tests for
independence were conducted. Statistical signiﬁcance was deﬁned as a
P-value of o0.05.
Continuous variables were assessed for normality using the Kolmogorov–Smirnov statistic. Nonparametric continuous variables were presented as medians and interquartile ranges (IQRs), whereas parametric
continuous variables were presented as means and s.d. Nonparametric
continuous variables were assessed using the Mann–Whitney U-test,
whereas parametric variables were assessed using independent-samples
t-tests or paired-samples t-tests as appropriate.

RESULTS
Case-matched analysis
The outcomes of newly diagnosed patients receiving EEN as their
ﬁrst treatment were compared with newly diagnosed patients
who received CS as their ﬁrst treatment. Twenty-eight patients
underwent EEN therapy at diagnosis. These patients were
matched for age, gender, disease location, disease behaviour
and disease activity (Table 1). There was no signiﬁcant difference
in age of diagnosis or gender between the two groups.
Remission details. Remission was achieved in a greater proportion of patients after treatment with EEN (24/28, 86%) compared
with CS (15/28, 54%; P = 0.02). No patients taking EEN required
extensions of therapy beyond the standard protocol. Ten patients
treated with CS required dose adjustments beyond the standard
protocol because of interval symptoms; six of these achieved
remission. By intention-to-treat analysis, 9/28 patients attained
remission on CS compared with 24/28 on EEN (P o0.001).
Adjunctive medications received during treatment were similar
between the cohorts, as documented in Table 1. Responses to
treatment as deﬁned by PCDAI are illustrated in Table 2.
Interestingly, although a signiﬁcant difference in remission rates
© 2017 Macmillan Publishers Limited, part of Springer Nature.
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Table 1. Age, gender, disease location, disease behaviour and disease
activity-matched EEN and CS cohorts for case-matched analysis
EEN (n = 28)
n (%)

CS (n = 28)
n (%)

Age of diagnosis
A1a
A1b

4 (14)
24 (86)

1 (4)
27 (96)

Gender
Male
Female

20 (71)
8 (29)

17 (61)
11 (39)

Location
L1
L1+L4a
L2
L2+L4
L3
L3+L4
L4

1 (4)
5 (18)
0
4 (14)
4 (14)
12 (43)
2 (7)

1 (4)
3 (11)
0
4 (14)
1 (4)
16 (57)
3 (11)

Behaviour
B1
B2
B3
B2B3
Perianal disease

20 (71)
6 (21)
2 (7)
0
11 (39)

21 (75)
6 (21)
1 (4)
0
7 (25)

Route of administration
Oral
Nasogastric
Intravenous

25 (89)
3 (11)
N/A

24 (86)
N/A
4 (14)

Type of feed
Polymeric
Elemental

28 (100)
0 (0)

N/A
N/A

9 (32)
3 (11)
7 (25)

16 (57)
6 (21)
6 (21)

Concomitant medication
Five ASAs
Immunomodulators
Antibiotics

Abbreviations: A1a, age 0– o10 years; Alb, age 10–17 years; 5ASA, 5aminosalicylic acid; B1, inﬂammatory; B2, stricturing; B3, penetrating; CS,
corticosteroids; EEN, exclusive enteral nutrition; L1, ileocaecal; L2, colonic;
L3, ileocolonic; L4a, oesophagus to ligament of Treitz; L4b, ligament of
Treitz to proximal ileum; N/A, not applicable. aL4 refers to any of L4a, L4b
and L4ab, per Paris classiﬁcation.

was observed between the cohorts, clinical response rates were
equivalent, with only one patient in each cohort not responding to
treatment. Disease activity designation was consistent between
Physician Global Assessment and PCDAI scores. The impact of
treatment on laboratory values is detailed in Table 3.
Relapse details. The median time to relapse in this EEN cohort
was 3 months (IQR: 4) and 2 months in the CS cohort (IQR: 3).
Thirteen patients (46%) who received EEN and 12 (43%) who were
treated with CS experienced a clinical relapse in the ﬁrst year after
treatment. Overall, there was no signiﬁcant difference in the
number of relapses observed in either cohort. The subsequent use
of immunomodulators also did not differ signiﬁcantly between the
groups (EEN, n = 23, 82%; CS, n = 22, 79%).
Medical and clinical nurse specialist contacts did not differ
between urban and rural dwellers and did not inﬂuence remission
rates. However, increased dietetic contacts during treatment were
independently associated with higher remission rates. Urbandwelling patients had a signiﬁcantly greater number of dietetic
© 2017 Macmillan Publishers Limited, part of Springer Nature.

contacts during EEN therapy and also had higher remission rates
than rural dwellers (5 vs 2.5; P = 0.03).
Growth parameters. An equal proportion of patients (5 vs 4) in
each cohort were classiﬁed as underweight on commencement of
treatment. Within each cohort, signiﬁcant changes in weight
z-scores were observed at the end of induction treatment, 1 year
after treatment and at maximum follow-up (Table 4). Height
z-scores declined in the CS but not in the EEN cohort during the
follow-up period (Table 4).
Upon subanalysis, ﬁve patients had signiﬁcant growth delay
pre-treatment (height z-score o − 2). The mean height z-score
after treatment with EEN (−0.65 ± 2.34, 2/28) was clinically superior
to that with the CS cohort (−2.43 ± 0.23, 3/28). At 1-year follow-up,
despite not reaching statistical signiﬁcance, the mean height
z-score of those treated with EEN remained clinically superior
(−0.53 ± 2.30, 2/28 vs − 2.35 ± 0.31, 3/28).
Cohort analysis
Two hundred and seventy-eight patients were diagnosed with CD
at OLCHC between 2004 and 2013. The characteristics of all
patients meeting the inclusion criteria (n = 59) are presented in
Table 5. Of the 59 patients who completed the 6- to 8-week course
of EEN, 57 patients (97%) took polymeric feeds and 2 patients (3%)
received elemental feeds. Overall, 51 patients (86%) consumed
feeds orally, with eight patients (14%) requiring tube feeding.
Thirty-ﬁve patients (59%) achieved 490% of their energy
requirements during the EEN treatment period, with 58 patients
(98%) meeting 490% of their protein requirements.
Remission details. Forty-one patients (69%) entered clinical
remission (PCDAI ⩽ 10) following EEN treatment. Greater remission
rates were observed in patients receiving EEN as an initial (25/29)
or subsequent (3/3) treatment rather than as a relapse treatment
(13/27; P = 0.004; Table 6). The use of EEN was not limited to
certain diagnostic phenotypes. There was no association between
diagnostic phenotype and attainment of remission. Clinical
remission rates were signiﬁcantly higher in older-onset paediatric
IBD (A1b) compared with those in early-onset IBD (A1a), as deﬁned
by the Paris classiﬁcation (P = 0.04). Patients who occasionally
consumed concomitant foods during EEN treatment had higher
remission rates (21/24, 88% vs 20/35, 57%; P = 0.03). Following
treatment, 49 patients (83%) continued on supplementary
polymeric enteral nutrition drinks. The study end point of
achieving remission was neither dependent on consuming
⩾ 90% of recommended daily protein or caloric intakes, nor
inﬂuenced by taking concomitant medications.
Changes in disease activity upon completion of treatment are
detailed in Table 2 for both study populations. Changes in
laboratory values following treatment are outlined in Table 3.
In total, 56 patients (95%) experienced a clinical relapse
according to the study deﬁnition in the ﬁrst year after treatment.
For patients who achieved remission, the median duration to
relapse was 2 months (IQR: 4.5 months), irrespective of the time of
EEN administration (initial, subsequent and relapse). Two patients
(3%) had a change in disease behaviour at 1-year follow-up.
Growth parameters. Changes in anthropometric parameters from
pre-treatment to maximum follow-up for the cohort analysis
population are detailed in Table 4. A mean weight gain of 4.4 kg
(±3.2) was observed with EEN treatment. Signiﬁcant improvements in weight z-scores were observed at all time-points,
whereas an improvement in height z-score was only seen at
maximum follow-up.
European Journal of Clinical Nutrition (2017) 185 – 191
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Table 2.

Disease activity before and after treatment as determined by PCDAIa

Case-matched analysis
EEN (n = 28)
Pre-treatment
Post-treatment
CS (n = 28)
Pre-treatment
Post-treatment
Cohort analysis
EEN (n = 59)
Pre-treatment
Post-treatment

Remission, n (%)

Mild, n (%)

Moderate, n (%)

Severe, n (%)

0 (0)
24 (86)

7 (25)
4 (14)

15 (54)
0 (0)

5 (18)
0 (0)

0 (0)
15 (54)

6 (21)
13 (46)

14 (50)
0 (0)

7 (25)
0 (0)

0 (0)
41 (69)

22 (37)
16 (27)

28 (47)
2 (3)

9 (15)
0 (0)

Abbreviations: CS, corticosteroids; EEN, exclusive enteral nutrition; mild, PCDAI 11–30; moderate, PCDAI 31–44; PCDAI, Paediatric Crohn’s Disease Activity
Index; remission, PCDAI ⩽ 10; severe, PCDAI ⩾ 45. aThis table presents results from analysis conducted, initially focusing on EEN vs CS as ﬁrst-line treatments at
diagnosis and subsequently a larger group of patients who were treated with EEN at any stage of their disease course. As illustrated in case-matched analysis,
pre-treatment of disease activity scores are rigorously matched, further strengthening comparison of post-treatment outcomes.

Table 3.

Mean laboratory parameters before and after treatmenta
Case-matched analysis

Cohort analysis

EEN (n = 28)

CS (n = 28)

EEN (n = 59)

CRP (mg/l)
Pre-treatment
Post-treatment

48
8

53
19

37
13

Platelets (x10 μl)
Pre-treatment
Post-treatment

557
355

544
422

488
371

Hb (g/l)
Pre-treatment
Post-treatment

112
118

109
113

113
117

HCT (%)
Pre-treatment
Post-treatment

34
48

33
35

35
40

3

ESR (mm/h)
Pre-treatment
Post-treatment

37
18

50
20

34
23

Albumin (g/dl)
Pre-treatment
Post-treatment

31
40

32
40

34
40

Abbreviations: CS, corticosteroids; CRP, C-reactive protein; EEN, exclusive
enteral nutrition; ESR, erythrocyte sedimentation rate; Hb, haemoglobin;
HCT, haematocrit. allustration of changes in laboratory parameters for
case-matched and cohort analysis groups from pre-treatment to posttreatment.

DISCUSSION
This study, in a nationally representative cohort, conﬁrms that
a 6–8-week course of EEN is an effective primary therapy for
inducing remission in paediatric CD, especially in patients over 10
years, and is dependent on the support of a trained dietitian.
Uniquely, this study is the ﬁrst to our knowledge to compare EEN
with CS by rigorously matching patients in terms of age, gender,
disease location, disease behaviour and disease activity, which
allowed for in-depth comparison of outcomes. Our results
illustrate that EEN is more effective than CS in inducing remission
European Journal of Clinical Nutrition (2017) 185 – 191

Table 4. Comparison of weight and height z-scores from pretreatment to maximum follow-up in patients who completed a full
treatment course
Weight z-score

Case-matched analysis
EEN (n = 28)
Pre-treatment
Post-treatment
One-year follow-up
Maximum follow-upb
CS (n = 28)
Pre-treatment
Post-treatment
One-year follow-up
Maximum follow-upb
Cohort analysis
EEN (n = 59)
Pre-treatment
Post-treatment
One-year follow-up
Maximum follow-upc

Height z-score

Mean ± s.d.

P-valuea

Mean ± s.d.

P-value

− 1.06 ± 1.12
− 0.38 ± 0.90
− 0.45 ± 0.96
− 0.09 ± 0.92

0.000
0.000
0.006

− 0.61 ± 1.07
− 0.68 ± 1.05
− 0.66 ± 1.11
− 0.37 ± 0.76

N/A
0.646
0.101

− 0.99 ± 1.30
− 0.26 ± 0.93
− 0.46 ± 1.16
− 0.43 ± 1.07

0.000
0.001
0.002

− 0.71 ± 1.06
− 0.88 ± 1.08
− 0.81 ± 1.09
− 0.92 ± 0.84

N/A
0.152
0.884

− 0.98 ± 1.32
− 0.40 ± 1.07
− 0.49 ± 1.28
− 0.31 ± 1.11

0.000
0.000
0.000

− 0.66 ± 1.2
− 0.67 ± 1.19
− 0.55 ± 1.19
− 0.36 ± 0.91

N/A
0.346
0.035

Abbreviations: CD, Crohn’s disease; CS, corticosteroids; EEN, exclusive
enteral nutrition; N/A, not applicable. EEN course as induction therapy for
CD from 2004 to 2013 (n = 59). aP-value o0.05 was considered statistically
signiﬁcant. bMaximum follow-up ranges from 0.31 to 7.31 years (median:
2.09 years). cMaximum follow-up ranges from 0.31 to 5.99 years (median:
2.04 years).

when used as the ﬁrst induction therapy at diagnosis. The results
afﬁrm the many recognised advantages of EEN, and our outcomes
compare favourably with published literature in this area,
especially with regard to remission rates and anthropometric
outcomes.8,10,14,22,23,33,34
Our ﬁnding that EEN was more effective clinically than CS at
inducing remission at diagnosis contrasts with previous reports of
their equivalent remission rates in paediatric populations.9,17,18,22,23,35
Our results give further support to the current recommendations
to use EEN as ﬁrst-line induction therapy in CD.16 We attempted to
mitigate potential bias and confounding factors by comparing
only patients who received EEN or CS as their ﬁrst treatment on
diagnosis. This rigorous matching signiﬁcantly reduced our
sample size. A comparison of mucosal healing between EEN and
© 2017 Macmillan Publishers Limited, part of Springer Nature.
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Table 5. Demographics of patients who completed a full EEN course
as induction therapy for CD from 2004 to 2013 (n = 59)

Table 6. Potential inﬂuencing factors on remission rates following
completion of a full course of EEN (n = 59)

n (%)
Gender
Male
Female
Age of diagnosis years (± IQR)
Mean age of commencement of EEN years (range)

39 (66)
20 (34)
12.34 ±3.82
13.27 (1.99–17.57)

Disease location
L1
L1+L4a
L2
L2 +L4
L3
L3+L4
L4

1 (2)
5 (8)
6 (10)
11 (19)
9 (15)
20 (34)
7 (12)

Disease behaviour
B1
B2
B3
B2B3
Perianal disease

48 (81)
8 (14)
2 (3)
1 (2)
21 (36)

Abbreviations: CS, corticosteroids; EEN, exclusive enteral nutrition; CD,
Crohn’s disease; L1, ileocaecal; L2, colonic; L3, ileocolonic; L4a, oesophagus
to ligament of Treitz; L4b, ligament of Treitz to proximal ileum; B1,
inﬂammatory; B2, stricturing; B3, penetrating. a‘L4’ refers to any of L4a, L4b
and L4ab, as per Paris classiﬁcation.

CS groups was not possible retrospectively, as routine posttreatment endoscopy is not appropriate in children, and faecal
calprotectin levels were not routinely measured.
EEN was most effective when used as an initial treatment in
newly diagnosed patients, especially in older children, irrespective
of diagnostic phenotype. An Australian study previously reported
better remission rates in newly diagnosed CD patients following
EEN treatment, compared with those with long-standing
disease.35 The lower 1-year relapse rate in the case-matched
EEN group compared with the overall post-EEN relapse rate
also suggests more favourable long-term beneﬁts when EEN is
used as a primary induction therapy. The low rates of progression
of disease location and behaviour observed in our cohort are in
keeping with previous reports from the Irish population.7
Emerging data have challenged historic opinion that only certain
inﬂammatory phenotypes of IBD respond effectively to
EEN.16,33,36,37 Our ﬁndings corroborate these data, reﬂecting
current prescription trends in the use of EEN, although not all
phenotypes were well represented (L2) within the limits of our
sample size.
Our study has identiﬁed novel disease-independent factors that
inﬂuenced EEN induction success. This is the ﬁrst study to show
that patients who were diagnosed over the age of 10 years were
more likely to attain remission on completion of treatment than
younger children. Whether higher success rates in older children
reﬂect better acceptability and compliance in this age group, or
underlying differences in disease biology, needs to be substantiated by further research. It remains intriguing why urbandwelling patients had better EEN success rates than rural dwellers.
Speculative reasons include more limited transportation, connectivity and dietetic access opportunities for children living in
remote locations. Patients with more dietetic contacts during
treatment also had higher rates of remission. This was independent of other multidisciplinary team member contacts. This
ﬁnding requires further validation, but has potentially signiﬁcant
implications for resource planning at paediatric IBD referral
© 2017 Macmillan Publishers Limited, part of Springer Nature.

Total, n

Remission
n (%)

P-valuea

0.004

Treatment type
Initial
Subsequent
Relapse

29
3
27

25 (86)
3 (100)
13 (48)

Age at diagnosis
A1a
A1b

17
42

8 (47)
33 (79)

0.039

Age at treatment (years)
0–o10
⩾ 10

12
47

7 (58)
34 (72)

0.556

Gender
Male
Female

39
20

28 (72)
13 (65)

0.812

41 (69)
18 (31)

0.025

Dietetic contactsb
⩾4
o4

Abbreviations: A1a, age o10 years; Alb, age 10–17 years; EEN, exclusive
enteral nutrition. aP-value o 0.05 was considered statistically signiﬁcant.
b
Dietetic contacts were deﬁned as direct (outpatient appointment, face to
face) or indirect (telephone or email).

centres, especially given the impetus to use EEN as primary
induction therapy.16 Our hospital protocol did not have deﬁned
guidelines regarding dietetic contacts upon discharge to community during the study period. Only two previous studies have
reported deﬁned protocols for dietitian contacts, but neither study
related this to treatment outcomes.37,38 Our protocol, in line with
current practice, recommends the use of polymeric feeds to help
improve tolerability.9,16 Consumption of small amounts of
additional foods during EEN treatment was associated with higher
remission rates. This may have improved EEN acceptance and
compliance, or helped to break the potential monotony of EEN
taste and texture. Recent studies have also found that EEN efﬁcacy
is not diminished signiﬁcantly when small volumes of certain
additional foods are consumed.12,33,39,40
We endeavoured to reduce the potential limitations involved in
our retrospective study and acknowledge those that remain.
Including only those patients who completed their EEN course
and not excluding those on concomitant therapies enabled us to
better reﬂect a ‘real-world’ experience of EEN. However, we
acknowledge that antibiotic therapy could have inﬂuenced
remission rates, given the potential anti-inﬂammatory effect of
these medications. A larger sample size and longer follow-up time
may have allowed detection of signiﬁcance in a number of
observed trends, and strengthened those we identiﬁed, especially
our anthropometric data. In particular, the illustrated superiority of
EEN may have been strengthened if multiple matching of CS
controls had been in place. As our study was retrospective,
researchers were reliant on chart notes to ascertain compliance,
and the brevity of these notes did not facilitate further exploration
of compliance challenges. Treatment selection was not randomised and was at physician and/or patient discretion. Our
retrospective study design did not enable us to explore physician
and patient factors regarding treatment choices and preferences,
leading to a potential for selection bias. Although this cannot be
absolutely excluded retrospectively, we attempted to compensate
for this, in part, by age-matching patients for disease activity as
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well as disease phenotype. It remains unclear whether EEN was
more likely to be offered to more motivated patients/families or to
older rather than younger patients. It is also possible that
induction treatments other than EEN were prescribed in severe
isolated colonic inﬂammatory disease, such as L2, B1. This may
have skewed patient representation and outcomes in these
groups. The effectiveness of all induction therapies used during
the study period lay outside the scope of the present study, but
would have allowed us to present more contextualised intentionto-treat analysis data of all treatment outcomes in our population.
In our group’s experience, patients who do not fully establish EEN
by day 7 do not persevere with it, and so commence alternative
treatments. Our retrospective study design did not enable us to
study potential barriers to completion of treatment. We also
interpret with caution our lack of EEN protocol breaches, which
reﬂects our relatively limited study size, as it is quite likely that a
much larger cohort would include such cases and affect results
accordingly. Further analysis of our more novel ﬁndings is
currently being evaluated in a prospective setting.
CONCLUSION
This study reafﬁrms the role and effectiveness of EEN in the
therapeutic armamentarium for treating paediatric CD, especially
as a ﬁrst-line induction strategy at diagnosis in older children. A
number of novel disease-independent factors have been identiﬁed that enhance EEN success, including the pivotal role of
dietitian contacts, allowing consumption of small amounts of nonnutritive foods during treatment and older age at diagnosis.
Future research on deﬁning EEN regimens, the efﬁcacy of EEN in
younger children and the inﬂuence of dietetic support and
protocols on treatment success and longer-term outcomes are
keenly awaited.
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